Form 8-K ATOSSA THERAPEUTICS, For: Oct 08

Fri, 09 Oct 2026 08:15:00 -0400

si-local-file:///var/storage/secattach/20261009/27169437.html

Atossa Therapeutics sets CVR plan tied to potential FDA voucher

Fri, 09 Oct 2026 08:01:19 -0400

Atossa Therapeutics, Inc. (Nasdaq: ATOS) has executed a Stapled Contingent Value Rights Agreement with VStock Transfer, LLC as rights agent, establishing a framework that gives shareholders a contractual stake in any proceeds from a potential FDA priority review voucher (PRV).

The company's board declared a dividend of one CVR for each share of Atossa common stock outstanding as of the close of business on October 19, 2026. Shares issued after that record date and before any CVR detachment or expiration will also carry one CVR. Under the agreement, CVR holders are entitled in aggregate to 25% of net proceeds from the

Atossa Therapeutics sets CVR plan tied to potential FDA voucher

Fri, 09 Oct 2026 08:01:19 -0400

Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value

Fri, 09 Oct 2026 08:00:00 -0400

Board declares one stapled CVR for each share of Atossa common stock outstanding as of October 19, 2026 record date or issued thereafter

CVRs entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying priority review voucher, subject to a $50 million aggregate payment cap

Atossa Therapeutics Executes Contingent Value Rights Agreement Providing Shareholders Participation in Potential Priority Review Voucher Value

Fri, 09 Oct 2026 08:00:00 -0400

Board declares one stapled CVR for each share of Atossa common stock outstanding as of October 19, 2026 record date or issued thereafter

CVRs entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying priority review voucher, subject to a $50 million aggregate payment cap

Atossa Therapeutics plans CVR tied to rare pediatric voucher

Tue, 29 Sep 2026 08:02:45 -0400

Atossa Therapeutics, Inc. (Nasdaq: ATOS) announced that its board of directors has approved a plan to issue one contingent value right (CVR) for each share of common stock, giving shareholders a contractual right to 25% of net proceeds from the monetization of the company's first qualifying rare pediatric disease priority review voucher, subject to a $50 million aggregate payment cap.

The CVRs would be issued to shareholders of record as of a record date to be announced, and shares issued after that date would also carry one CVR per share. The CVRs would not trade separately from Atossa shares, will not

Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher

Tue, 29 Sep 2026 08:00:00 -0400

Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereafter

CVRs would entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying priority review voucher, subject to a $50 million aggregate payment cap

SEATTLE, Sept.

Atossa Therapeutics Announces Plan to Issue Stapled CVR for Shareholders Tied to Potential Rare Pediatric Disease Priority Review Voucher

Tue, 29 Sep 2026 08:00:00 -0400

Shareholders would receive one CVR for each ATOS share held as of the record date or issued thereafter

CVRs would entitle holders to 25% of net proceeds from monetization of Atossa's first qualifying priority review voucher, subject to a $50 million aggregate payment cap

SEATTLE, Sept.

Form 8-K ATOSSA THERAPEUTICS, For: Sep 29

Tue, 29 Sep 2026 08:00:00 -0400

si-local-file:///var/storage/secattach/20260929/27117707.html

Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging

Thu, 24 Sep 2026 08:00:00 -0400

Panel at Harvard University will explore translating evidence in diseases of aging into new therapeutics and regulatory pathways

SEATTLE, Sept. 24, 2026 /PRNewswire/ -- Atossa Therapeutics, Inc. (Nasdaq: ATOS) ("Atossa" or the "Company"), a clinical-stage biopharmaceutical company, today announced that Steven Quay, M.D., Ph.D., Atossa's President and Chief Executive Officer, will participate as a panelist

Atossa Therapeutics CEO Dr. Steven Quay to Participate in ARDD 2026 Panel on Clinical Trials and Regulatory Pathways for Diseases of Aging

Thu, 24 Sep 2026 08:00:00 -0400

Panel at Harvard University will explore translating evidence in diseases of aging into new therapeutics and regulatory pathways

Form 8-K ATOSSA THERAPEUTICS, For: Sep 18

Fri, 18 Sep 2026 17:00:00 -0400

si-local-file:///var/storage/secattach/20260918/27081208.html

Atossa Genetics (ATOS) Tops Q2 EPS by 10c

Fri, 07 Aug 2026 08:59:15 -0400

Atossa Genetics (NASDAQ: ATOS) reported Q2 EPS of ($0.95), $0.10 better than the analyst estimate of ($1.05).

For earnings history and earnings-related data on Atossa Genetics (ATOS) click here.

Form 8-K ATOSSA THERAPEUTICS, For: Aug 07